ALA-002

all catalysts(0)

nothing on the calendar yet

News(2)

• Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
  A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…
  biopharma_dive · 26d ago
• Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug
  Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
  fiercebiotech · 28d ago